Medicines that promise to lose weight with health, arrive in the country and are already being used by patients in the state. See how each one works
| Photo: Canva
Losing weight is considered a challenge for many people. For those who live with this reality, news brings hope: new pills and injections that promise to lose weight have already hit the market and others should soon arrive in Brazil.
One of them is oral semaglutide (brand name, Rybelsus), from Novo Nordisk, already approved by the National Health Surveillance Agency (Anvisa), which is against type 2 diabetes and has also helped those who need to lose weight. The drug should be taken daily, on an empty stomach, at least half an hour before breakfast.
Oral semaglutide, according to the pharmaceutical company, is the first GLP-1 agonist (a hormone that optimizes the production of insulin in the blood and promotes the feeling of satiety) in a pill and is available in Brazil for the treatment of adults with poorly controlled type 2 diabetes. , in order to improve glycemic control, in association with diet and physical exercise.
Another drug that generates weight loss, whose effect is similar to bariatric surgery, should soon arrive in Brazil. The company that sells the medication, Eli Lilly, is awaiting authorization from Anvisa to release its use. It is estimated that it should arrive in the country in 2023.
Cities Pills and injection to lose weight In the photo Mônica Campos de Oliveira Photo: Leone Iglesias
| Photo: Leone Iglesias/AT
On a daily basis, hairdresser and beautician Mônica Campos de Oliveira, 46, takes care of her and her clients’ beauty, health and well-being.
Vain, she says that she would have the courage to take drugs to lose weight and rejuvenate, as long as she had scientific proof of effectiveness.
Monica says that she drinks teas that help control weight, such as green tea. “I’ve had hibiscus tea, but I stopped, because it’s not suitable for those who have gastritis, like me”.
Sabrina França, an endocrinologist, says that Ozempic (injectable Semaglutide) and Rybelsus (oral Semaglutide) are already on the market. “Both medications are for the treatment of diabetes, but they help with weight loss”.
But she reinforces that because they have side effects such as nausea, diarrhea or constipation, the drugs must be prescribed and monitored by the endocrinologist, and never be used on their own.
According to her, injectable Semaglutide has already been approved in the United States for the treatment of obesity in non-diabetics under the name of Wegovy, and has shown excellent results.
Queulla Garret, endocrinologist, highlights that Tirzepatida is an injectable, subcutaneous medication, taken once a week. About Rybelsus, she says that she has already prescribed it to some patients and the result is being very good.
Fernanda Zottich Loureiro, endocrinologist and metabologist, concludes by saying that the treatment of obesity is individualized. “Tirzepatide did not come to replace bariatric surgery.”
A pill against type 2 diabetes that has also helped those who need to lose weight has arrived in Brazil. It is oral semaglutide (trade name – Rybelsus), from Novo Nordisk, which has already been approved by the National Health Surveillance Agency (Anvisa).
The new drug is the oral tablet version of semaglutide.
The new drug is available in doses of 3mg, 7mg and 14mg, in order to facilitate adaptation to treatment, according to the patient’s needs.
Each product box contains 30 pills (three packs with 10 pills each).
The drug should be taken daily, on an empty stomach, at least half an hour before breakfast.
The Maximum Consumer Price (PMC) of the Rybelsus product is R$ 515 for the 3mg presentation, and R$ 1,165.90 for the 7mg and 14mg presentations each (PMC 18%), varying with the incidence of tax of 12 % to 20%, depending on the Federative Unit.
It is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), a new class of medication for the treatment of obesity and diabetes. It is already being used in the United States and should arrive in Brazil soon.
Tirzepatide is given as a weekly subcutaneous injection. There is still no information about the price of the drug.
The company that sells the medication, Eli Lilly, is awaiting authorization from the National Health Surveillance Agency (Anvisa) to release the use of the medication in the country. If approved, it should be available in the second half of 2023.
A clinical study demonstrated weight loss similar to that obtained with bariatric surgery.
Physicians interviewed emphasize that any medication, surgery or intervention only makes sense within a complete treatment against obesity, a chronic disease that requires long-term follow-up .
Source: Physicians interviewed and survey A Tribuna.
#Pills #Injections #Weight #Loss #Online #Tribune